Dr. Pierre-Allain Girod to Present on Data on Engineering CHO Cell Lines for Enhanced Production of Monoclonal Antibodies and Fc:Fusion Proteins
Geneva, Switzerland (PRNEWSWIRE) August 31, 2011 – Selexis SA, a global life science company with technologies for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins announced today the Company’s chief scientific officer, Pierre-Allain Girod, PhD, will present, “Engineering CHO Cell Line For Enhanced Production of MAbs and Fc:Fusion Proteins” on Tuesday, November 8, 2011 at the 16th Annual Human Antibodies and Hybridomas Conference being held November 7 – 9, 2011 in Cannes, Frances at the Novotel Cannes Montfleury.
The Chinese hamster ovary (CHO) cell line is the predominant host for the production of therapeutic proteins. However, the CHO cell for the production of Fc:fusion at a high level is notorious for poor performance. We identified components of the secretion network able to enhance the yield of recombinant proteins. Co-expression of secretion components improved cell lines expression at protein concentrations of greater than 1 gr/L in a fed-batch process.
For more information and registration, please visit the Human Antibodies and Hybridomas 2011 Conference website at http://www.meetingsmanagement.com/hah_2011